Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Liabilities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Liabilities for 8 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 18.62% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Dec 2025, down 18.62% year-over-year, with the annual reading at $14.5 million for FY2025, 18.62% down from the prior year.
  • Total Liabilities for Q4 2025 was $14.5 million at Whitehawk Therapeutics, up from $9.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $27.2 million in Q4 2023, with the low at $2.1 million in Q1 2021.
  • Average Total Liabilities over 5 years is $17.4 million, with a median of $18.8 million recorded in 2021.
  • The sharpest move saw Total Liabilities skyrocketed 801.5% in 2022, then plummeted 61.65% in 2025.
  • Over 5 years, Total Liabilities stood at $21.5 million in 2021, then increased by 20.25% to $25.9 million in 2022, then grew by 5.29% to $27.2 million in 2023, then tumbled by 34.48% to $17.8 million in 2024, then decreased by 18.62% to $14.5 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $14.5 million, $9.8 million, and $8.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.